Overview

Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)

Status:
Withdrawn

Trial end date:
2010-07-01

Target enrollment:

Participant gender:

Summary

Many chemotherapy combinations may be used to treat patients with chronic lymphocytic leukemia (CLL). Although there are many options, a single, best option is not agreed upon by most cancer specialists. Bendamustine, a medicine recently approved for use in the United States, has been used in combination with rituximab in previous studies to treat patients whose CLL has returned after previous standard treatments. The purpose of this study is to determine whether bendamustine with rituximab is effective for the initial treatment of CLL for patients aged 65 and older.

Phase:

Phase 2

Details

Lead Sponsor:

University of Kentucky

Collaborator:

Cephalon

Treatments:

Bendamustine Hydrochloride
Rituximab